Merck Animal Health Launches NOBIVAC® Global Vet Exchange
Veterinarians Share Best Practices for Improving Animal Care Globally
SUMMIT, N.J., November 20, 2014 – Merck Animal Health (known as MSD Animal Health outside the USA and Canada) today announced the launch of the NOBIVAC® Global Vet Exchange Program, which will give ten veterinarians the opportunity to visit clinics in other countries and share their knowledge and experience in veterinary care.
“The NOBIVAC Global Vet Exchange will facilitate dialogue between veterinarians across the globe, helping them learn new ideas and share best practices for improving animal care,” said Karin Jager, Merck Animal Health. “Through this program, Merck Animal Health aims to offer a rewarding learning experience, not only for the veterinarians participating in the exchange, but also for those following through blogs and videos that will be shared online.”
For the first year of the exchange, ten veterinarians from China, Japan, the Netherlands, the United Kingdom and the United States will visit each other’s clinics to experience working in a new clinic in a different country. The participating veterinarians will share their experiences through blog entries and videos on vetexchange.nobivac.com. Dr. Link Welborn, of Tampa, Florida, U.S.A., and Dr. Roeland Wessels, of the Netherlands, will officially launch the program when they travel to a clinic in Japan this month.
“The Global Vet Exchange Program will allow veterinarians like me to discover, compare, and contrast the way I work in my own country and practice,” said Dr. Wessels. “I am excited to meet fellow veterinarians and share our knowledge to help improve the care of companion animals.”
To learn more about the NOBIVAC Global Vet Exchange, see updates from participating veterinarians, and learn how you can participate in the exchange, visit vetexchange.nobivac.com.
About Merck Animal Health
Today’s Merck is a global healthcare leader working to help the world be well. Merck Animal Health, known as MSD Animal Health outside the United States and Canada, is the global animal health business unit of Merck.Through its commitment to the Science of Healthier Animals™ , Merck Animal Health offers veterinarians, farmers, pet owners and governments one of the widest range of veterinary pharmaceuticals, vaccines and health management solutions and services. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com or connect with us on LinkedIn .
Merck forward-Looking Statement
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site ( www.sec.gov ).